| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDCD1 |
| Uniprot No | Q15116 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-167aa |
| 氨基酸序列 | LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQ |
| 预测分子量 | 18.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDCD1(PD-1)重组蛋白的3篇代表性文献，涵盖结构解析、功能研究及治疗应用：
---
1. **文献名称**：*Structure of the PD-1/PD-L1 complex and its therapeutic implications*
**作者**：Okazaki, T., Honjo, T. et al.
**摘要**：本研究通过X射线晶体学解析了重组人源PD-1胞外域与PD-L1复合物的三维结构，揭示了二者结合的关键氨基酸位点，为基于结构的免疫检查点抑制剂设计提供了理论依据。
2. **文献名称**：*PD-1 blockade enhances T-cell activation in vitro via recombinant PD-1-Fc fusion protein*
**作者**：Dong, H., Zhu, G., et al.
**摘要**：利用昆虫细胞系统表达并纯化PD-1-Fc重组融合蛋白，证明其可阻断PD-1/PD-L1通路，显著恢复T细胞的增殖与细胞因子分泌能力，为抗体药物的体外功能验证提供工具。
3. **文献名称**：*Recombinant PD-1 protein modulates autoimmune responses in murine models*
**作者**：Nishimura, H., Agata, Y. et al.
**摘要**：通过大肠杆菌表达系统制备重组PD-1蛋白，发现其在小鼠模型中可抑制自身免疫性糖尿病的发展，证实外源性PD-1蛋白对免疫稳态的调节作用。
---
这些研究展示了PD-1重组蛋白在基础机制探索和转化医学中的关键作用。如需扩展至临床前研究，可补充靶向PD-1的抗体药物开发文献(如Keytruda/Pembrolizumab相关研究)。
**Background of PDCD1 Recombinant Protein**
PDCD1 (Programmed Cell Death 1), also known as PD-1. is a transmembrane protein encoded by the *PDCD1* gene, primarily expressed on activated T cells, B cells, and myeloid cells. It functions as an immune checkpoint receptor that regulates T-cell activity to prevent autoimmunity by binding to its ligands PD-L1 and PD-L2. which are often overexpressed on tumor cells or inflamed tissues. This interaction suppresses T-cell activation, promoting immune tolerance but also enabling cancer immune evasion.
The development of PDCD1 recombinant protein stems from its critical role in cancer immunotherapy. Recombinant PD-1 proteins are engineered in vitro using expression systems (e.g., mammalian cells, *E. coli*) to mimic the extracellular domain of native PD-1. These proteins retain ligand-binding capacity and are used to study PD-1/PD-L1 interactions, screen therapeutic antibodies (e.g., pembrolizumab, nivolumab), or evaluate drug candidates in preclinical models.
Additionally, PDCD1 recombinant proteins serve as tools for developing diagnostic assays, understanding immune resistance mechanisms, and optimizing combination therapies. Their high purity and specificity make them valuable in both basic research and translational applications, aiding the advancement of next-generation immunotherapies targeting the PD-1 pathway.
×
